TTY Biopharm Co (ROCO:4105) Change In Receivables : NT$54 Mil (TTM As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is TTY Biopharm Co Change In Receivables?

TTY Biopharm Co's change in receivables for the quarter that ended in Dec. 2024 was NT$31 Mil. It means TTY Biopharm Co's Accounts Receivable declined by NT$31 Mil from Sep. 2024 to Dec. 2024 .

TTY Biopharm Co's change in receivables for the fiscal year that ended in Dec. 2024 was NT$54 Mil. It means TTY Biopharm Co's Accounts Receivable declined by NT$54 Mil from Dec. 2023 to Dec. 2024 .

TTY Biopharm Co's Accounts Receivable for the quarter that ended in Dec. 2024 was NT$1,331 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. TTY Biopharm Co's Days Sales Outstanding for the three months ended in Dec. 2024 was 70.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. TTY Biopharm Co's liquidation value for the three months ended in Dec. 2024 was NT$1,363 Mil.

TTY Biopharm Co Change In Receivables Historical Data

The historical data trend for TTY Biopharm Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TTY Biopharm Co Change In Receivables Chart

TTY Biopharm Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

67.81

-116.19

-96.89

-119.90

54.13

TTY Biopharm Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-24.03	124.64	-6.44	-95.37	31.30

TTY Biopharm Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$54 Mil.

TTY Biopharm Co (ROCO:4105) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

TTY Biopharm Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1330.825	/	1712.127	*	91
=	70.93

2. In Ben Graham's calculation of liquidation value, TTY Biopharm Co's accounts receivable are only considered to be worth 75% of book value:

TTY Biopharm Co's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3081.63	-	3351.826	+	0.75 * 1330.825	+	0.5 * 1270.007
=	1,363

TTY Biopharm Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of TTY Biopharm Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

TTY Biopharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503

Website

https://www.tty.com.tw

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

TTY Biopharm Co Headlines

No Headlines